Content Status

Type

Linked Node

H5Content
Content

Longer oral Multi (M)/ Extensively-drug Resistant TB (XDR-TB) regimen is recommended for Multi-drug Resistant (MDR)/ Rifampicin-resistant TB (RR-TB) patients who are excluded from shorter oral Bedaquiline-containing MDR/ RR-TB regimen including for the XDR-TB patient. 

 

A patient would be re-evaluated in any of the following conditions and initiated on a longer oral M/XDR-TB regimen at Nodal (N)/ District DR-TB Centre (DDR-TBC) with any modifications:

  • Additional resistance
  • Intolerance or non-availability of any drug in use 
  • Emergence of exclusion criteria 
  • Return after lost-to-follow-up (LTFU) 
  • Failed to shorter oral Bedaquiline-containing MDR/ RR-TB regimen or any longer regimen 

 

The decision will also be based on Drug Susceptibility Test (DST) results, especially for Levofloxacin (Lfx), Moxifloxacin (Mfx), Bedaquiline* (Bdq), Linezolid (Lzd), Clofazimine* (Cfz), Delamanid* (Dlm) and Pyrazinamide (Z) (*whenever available).

 

The regimen modification would be done using a replacement of the sequence from group C drugs.

 

Resources

 

 

Kindly provide your valuable feedback on the page to the link provided HERE

Page Tags

Content Creator

Reviewer

Comments

Dr. Priyadarshini Tue, 09/01/2024 - 14:36

First paragraph to be rephrased. Treatment for person with XDR-TB not clearly brought out.